Current treatment of myelofibrosis based on risk stratification of patients
Authors:
M. Palová; K. Indrák; A. Hluší; T. Szotkowski
Authors‘ workplace:
Hemato-onkologická klinika, LF UP a FN Olomouc
Published in:
Transfuze Hematol. dnes,19, 2013, No. 3, p. 163-170.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Primary myelofibrosis belongs to the group of Ph1-negative myeloproliferative neoplasms, along with essential thrombocythemia and polycythemia vera, which may also progress to a fibrotic stage. Risk stratification of patients is especially important for proper therapeutic decision making and selection of high risk patients suitable for allogeneic stem cell transplantation, the only curative option for myelofibrosis. Transplantation carries a significant risk of mortality and morbidity, therefore it is recommended in patients with a median survival of less than 5 years. The recently introduced Dynamic International Prognostic Scoring System-plus prognostic model uses eight independent predictors of inferior survival. Janus 2 kinase inhibitors present a new targeted therapy affecting pathogenetic signal pathways. The results of on-going studies will show their long-term efficacy, safety and impact on overall survival.
Key words:
myelofibrosis, splenomegaly, JAK2V617F mutation, JAK2 inhibitors
Sources
1. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 142-150.
2. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012; 158: 453-471.
3. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005; 105: 973-977.
4. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood 2009; 113: 2895-2901.
5. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 222-230.
6. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International working group for myelofibrosis research and treatment). Blood 2010; 115: 1703-1708.
7. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
8. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118(17): 4595-4598.
9. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011; 12(10): 1597-1611.
10. Ballen K, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
11. Stewart WA, Pearce R, Kirkland KE, et al. The role of allogeneic SCT in primary myelofibrosis: a British society for blood and marrow transplantation study. Bone Marrow Transplant 2010; 45: 1587-1593.
12. Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J; publikováno elektronicky 2. března 2012. DOI 10.1038/bcj-2012-3
13. Steckel NK, Koldehoff M, Ditschkowski M, et al. Use of the activating gene station of the tyrosine kinase JAK2 as a minimal disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518-1520.
14. Bacigalupo A, Soraru M, Dominietto A, et al. Allogeneic hematopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size, and donor type. Bone Marrow Transplant 2010; 45: 458-463.
15. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288-296.
16. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.
17. Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednison based regimens. Am J Hematol. 2011; 86(1): 96-98.
18. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760-4766.
19. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5q)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21(8): 1827-1828.
20. Tefferi A. How I treat myelofibrosis. Blood 2011; 117(13): 3949-3504.
21. Mesa RA, Nagomey DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
22. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis – new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol; publikováno elektronicky 1. srpna 2012. DOI: 10.1186/1756-8722-5-43
23. Sirhan S, Lasho TL, Hanson CA, et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden on polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83: 363-365.
24. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009; 113: 5394-5400.
25. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 116: 576-581.
26. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
27. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid melignancies. Blood 2011; 117: 4706-4715.
28. Verstovsek S, Lawhorn K, Giles F, et al. PEG-intron for myeloproliferative diseases: an update of ongoing phase II study. Blood 2004; 104: Abstract 633.
29. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-INF-alpha-2a therapy in patients with myelofibrosis: a study of the french groupe d etudes des myelofibroses (GEM) and France intergroupe des syndromes myéloprolifératifs (FIM). Br J Haematol 2009; 146: 223-225.
30. Hubáček J, Faber E, Indrák K. Podpůrná terapie megestrol acetátem u myeloproliferativních neoplazií. Transfuze Hematol dnes 2012; 4: 174-176.
31. Elliott MA, Chen MG, Silverstein MN, et al. Splenic iradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998; 103: 505-511.
32. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednison for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.
33. Barbui T, Carrobio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115(4): 778-782.
34. Cross NC. Genetic and epigenetic komplexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011; 2011: 208-214.
35. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function station of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
36. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
37. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-789.
38. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365: 1455-1457.
39. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118(8): 2069-2076.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 3
Most read in this issue
- Current treatment of myelofibrosis based on risk stratification of patients
- Lymphomas of gastrointestinal tract – clinico-pathological review
- The importance of serum immunoglobulin free light chain assay in AL amyloidosis
- Plasma cell leukaemia